Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Hepatology Research"
DOI: 10.1111/hepr.14104
Abstract: When evaluating response to immune checkpoint inhibitor therapy, the tumor sometimes initially swells before shrinking and ultimately responding, also called pseudo‐progression. In this study, we analyzed whether tumor markers were useful for reflecting the treatment… read more here.
Keywords: significance changes; therapy; tumor markers; changes tumor ... See more keywords